TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02822157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Description: physician's choice chemotherapy
Study: NCT01525667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 150M PLX-PAD
Description: Single course, multiple IM injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300M PLX-PAD
Description: Single course, multiple IM injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single course, multiple IM injections
Study: NCT03301233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate and sildenafil
Description: (45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate and sildenafil
Description: (45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
Study: NCT02435862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0mg Luminate®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0mg Luminate®
Study: NCT00635349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride Plus Acetaminophen
Description: Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
Study: NCT02435862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.0mg Luminate®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution for intravitreal injection in 0.10cc
Study: NCT02565277

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01131845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR (treprostinil diethanolamine)
Description: Single dose, 1 mg UT-15C SR
Study: NCT04252261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulforaphane
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placedo
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
Study: NCT01112982

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).

Intervention type: DRUG
Group type: OTHER
Intervention: Febuxostat
Description: All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is \> 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine
Description: Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
Study: NCT00633048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01395355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linking Individuals Being Emotionally Real (LIBER8)
Description: Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management Control
Description: Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
Study: NCT00927758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Description: fluticasone propionate/salmeterol diskus
Study: NCT01482455

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elevation of FFA during OGTT
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elevation of FFA during OGTT
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elevation of FFA during Clamp
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elevation of FFA during Clamp
Description: 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1.
Study: NCT00409916

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioZ Dx

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BioZ Dx
Study: NCT01476761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcutter XPRESS and Microcutter XCHANGE
Description: Surgical stapling devices
Study: NCT00114218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study: NCT02746770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Cawthorne and Cooksey exercises group
Description: Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
Study: NCT02884128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
Study: NCT02319408

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Description: Lobectomy for lung cancer following preoperative radiation
Study: NCT01020032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual receptive music therapy by U sequence method
Description: During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
Study: NCT04595409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYB202 (Proposed ustekinumab biosimilar)
Description: Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara® (Ustekinumab)
Description: Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
Study: NCT02645461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocannabinoid palmitoylethanolamide (PEA)
Description: Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 50 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: Riluzole 50 mg twice daily
Study: NCT00095719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
Study: NCT00968708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Alogliptin placebo matching tablets
Study: NCT02992418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: 0.5 mL, intramuscularly at Day 0.
Study: NCT01011179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens Taking Charge
Description: The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management
Description: Adolescents' own best efforts at managing their JIA
Study: NCT03048188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing
Description: Manuka honey wound dressing
Study: NCT00288041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT01372774

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole-brain radiation therapy
Description: Undergo radiotherapy (RT)
Study: NCT02537119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic massage therapy
Description: Dynamic massage therapy on hamstring combined with knee extension
Study: NCT00635349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride Plus Acetaminophen
Description: Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
Study: NCT04325295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Description: LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FSH (rFSH)
Description: A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
Study: NCT02537119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Rubbing on hamstrings
Study: NCT02837328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Magnesium Supplement
Description: 400 mg Magnesium Citrate 1x daily for 12 weeks
Study: NCT00690690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video (group-delivered video-based intervention)
Description: group-delivered video-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCT
Description: Offer of HIV counseling and testing
Study: NCT04461873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki by touching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Reiki
Description: Sham reiki by gesturing and mimic imitation through touching
Study: NCT04356846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108 tablet
Description: Taken orally within 30 minutes after a meal at the designated dose, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108 tablet
Description: Taken orally within 30 minutes after a meal at the designated dose, once daily.
Study: NCT03277001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40mg IH
Study: NCT03949452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Transversus Abdominis Plane catheter
Description: Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Epidural catheter
Description: Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively.
Study: NCT04424459

Intervention type: DRUG
Intervention: opioid withdrawal
Description: The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
Study: NCT02837328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Study: NCT01341535

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive dose-painting-by-numbers
Description: Adaptive dose escalation by dose-painting-by-numbers.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard intensity-modulated radiotherapy (IMRT)
Description: Standard radiotherapy for head and neck cancer.
Study: NCT04563403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Projection-based augmented reality therapy (P-ARET)
Description: The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Projection-based augmented reality therapy (P-ARET)
Description: The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention.
Study: NCT00288041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT03396497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYC-55716
Description: Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
Study: NCT04482439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivity Extended Depth of Focus intraocular lens (IOL)
Description: Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
Study: NCT03438708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Oral Tablet [Inlyta]
Description: Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
Study: NCT03018535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab,1 g IV, day 1 and day 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days